Seegene Inc
상단으로
Contact Us

Product News You can check out the latest product information

  • Obtained CE-IVD marking for assays that detects MTB and Multi-Drug Resistance and Extensively Drug Resistance

    Seegene has received CE-IVD mark under European Union on?In Vitro?Diagnostics Medical Devices for Allplex™ MTB/MDR/XDRe Detection, Allplex™ MTB/MDRe Detection, Allplex™ MTB/XDRe Detection. Based on Seegene's proprietary DPO™ and TOCE™ technology, these assays are multiplex real-time PCR assay that detects and identifies?Mycobacterium tuberculosis (MTB) and 25 mutations associated with Multi-Drug Resistance (MDR) and 13 mutations associated with Extensively Drug Resistance (XDR). These assays enable to deliver MTB and Drug-resistant TB result in one day, which helps effective management of tuberculosis.

    Oct 29, 2018 Allplex™ MTB/XDRe Detection

  • Obtained CE-IVD marking for Anyplex™ MTB/NTMe Real-time Detection

    Seegene has received CE-IVD mark under European Union on In Vitro Diagnostics Medical Devices for Anyplex™ MTB/NTMe Real-time Detection. This assay is a Real-time PCR assay to detect simultaneously Mycobacterium tuberculosis dissociated from non-tuberculosis mycobacteria and include whole process control for assay validity.

    May 12, 2017 Anyplex™ MTB/NTMe Real-time Detection

  • Launched Anyplex™ II MTB/MDR/XDR Detection

    Tuberculosis is caused by Mycobacterium tuberculosis infection and it’s mostly transmitted through the air. Recently, the number of drug- resistant mycobacterium tuberculosis has been increased in worldwide due to the spread of drug-resistant mycobacterium tuberculosis infection or improper treatment when tuberculosis is first diagnosed. The Anyplex™ II MTB/MDR/XDR Detection has been specifically designed to address this unmet medical need through the simultaneous detection, Screening of MTB, MDR-TB and XDR-TB contributing to TB infection. Based on Seegene’s proprietary DPO™ and TOCE™ technologies, this homogeneous assay performs on standard existing real-time PCR instrumentation to detect, MTB, 25 MDR mutations and 13 XDR mutations. This product can help you to properly manage the tuberculosis and provides effective treatment guidelinesAnyplex™ II MTB/MDR/XDR? DetectionSimultaneous detection of MTB, MDR-TB and XDR-TBAnyplex™ II MTB/MDR/XDR Detection detects MTB, MDR-TB and XDR-TB in a single real-time PCR.

    Sep 14, 2012 Anyplex™Ⅱ MTB/MDR/XDR Detection

  • Obtained CE-IVD marking for Anyplex™ plus MTB/NTM/DR-TB Detection

    Anyplex™ plus MTB/NTM/DR-TB Detection Detection and discrimination of MTB/NTM & MDR-TB Seegene's Anyplex™ plus MTB/NTM/DR-TB Detection has been notified at Germany CA (Competent Authorities). The CE mark will allow more opportunities for Seegene to market and sell within the European Union.

    Nov 17, 2011 Anyplex™ plus MTB/NTM/DR-TB Detection

  • Launched Total Solution of Tuberculosis Diagnosis

    Seegene has launched Magicplex™ Sepsis Real-time Test

    Jul 25, 2011 Anyplex™ plus MTB/NTM/MDR

  • Launched Magicplex™ TB/MDR Real-time Test

    Magicplex™ TB/MDR Real-time TestMagicplex™ TB/MDR Real-time Test detects Mycobacterium tuberculosis (MTB) and screens Multidrug-resistant Mycobacterium tuberculosis (MDR-TB) on Real-time PCR.

    Dec 01, 2010 Magicplex TB/MDR Real-time Test

  • Obtained CE-IVD marking for Magicplex™ MTB Real-time Test

    Detection of Mycobacterium tuberculosis Seegene's Magicplex™ MTB Real-time Test has been notified at Germany CA (Competent Authorities). The CE mark will allow more opportunities for Seegene to market and sell within the European Union.      

    Aug 16, 2010 Magicplex MTB Real-Time Test

  • Obtained CE-IVD marking for Anyplex™ MTB/NTM Real-time Detection

    Anyplex™ MTB/NTM Real-time DetectionIdentification of MTB dissociated from NTM Seegene's Anyplex™ MTB/NTM Real-time Detection?has been notified at Germany CA (Competent Authorities). The CE mark will allow more opportunities for Seegene to market and sell within the European Union.

    Jul 12, 2010 Anyplex™ MTB/NTM Real-time Detection